Septerna Inc. Common Stock (SEPN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Septerna Inc. Common Stoc... (SEPN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

16.51

-0.45 (-2.65%)

At close: Jan 15, 2025, 1:36 PM

undefined% (undefined)

Bid	16.33
Market Cap	733.09M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.47
PE Ratio (ttm)	-35.13
Forward PE	n/a
Analyst	Buy

Ask	16.69
Volume	37,653
Avg. Volume (20D)	361,270
Open	17.15
Previous Close	16.96
Day's Range	16.50 - 17.19
52-Week Range	15.86 - 28.99
Beta	undefined

About SEPN

A detailed description of the company is not yet available....

[Show more]

Industry n/a

Sector n/a

IPO Date n/a

Employees 68

Stock Exchange NASDAQ

Ticker Symbol SEPN

Analyst Forecast

According to 4 analyst ratings, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $43, which is an increase of 160.45% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

News

1 month ago · benzinga.com

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.

2 months ago · seekingalpha.com

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, Septerna, and WeRide. Several small issuers also listed this past week, includin...

2 months ago · reuters.com

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.

2 months ago · reuters.com

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.

2 months ago · reuters.com

Biotech Septerna aims to raise up to $186 million in US IPO

Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.